Novartis AG ADR (NVS)vsTwist Bioscience Corp (TWST)
NVS
Novartis AG ADR
$148.38
-0.17%
HEALTHCARE · Cap: $289.19B
TWST
Twist Bioscience Corp
$85.17
-6.37%
HEALTHCARE · Cap: $4.74B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 13717% more annual revenue ($56.58B vs $409.48M). NVS leads profitability with a 23.9% profit margin vs -19.9%. NVS earns a higher WallStSmart Score of 49/100 (D+).
NVS
Hold49
out of 100
Grade: D+
TWST
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-62.6%
Fair Value
$91.58
Current Price
$148.38
$56.80 premium
Margin of Safety
+58.3%
Fair Value
$119.02
Current Price
$85.17
$33.85 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Conservative balance sheet, low leverage
19.3% revenue growth
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Trading at 11.6x book value
0.0% earnings growth
ROE of -17.9% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : TWST
The strongest argument for TWST centers on Debt/Equity, Revenue Growth. Revenue growth of 19.3% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : TWST
The primary concerns for TWST are Price/Book, EPS Growth, Return on Equity.
Key Dynamics to Monitor
NVS profiles as a declining stock while TWST is a growth play — different risk/reward profiles.
TWST carries more volatility with a beta of 2.21 — expect wider price swings.
TWST is growing revenue faster at 19.3% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 26/100), backed by strong 23.9% margins. TWST offers better value entry with a 58.3% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Twist Bioscience Corp
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company is headquartered in South San Francisco, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?